In this cohort of relapsed/refractory Burkitt lymphoma patients, the prognostic impact of mutations in TP53, MYC, ID3, CCND3, KRAS, and FAT4 remains unclear. The gene discussed is KRAS; the disease is Burkitt lymphoma.